


EDUCATION GRAMTM **Recommendations For The Treatment Of Neuropathic Pain**

Vol 14 No. 03 | February 2016

According to the International Association for the Study of Pain (IASP), neuropathic pain (NP) is "initiated or caused by a primary lesion or dysfunction in the nervous system", and damage in the peripheral or central nervous system is often due to common diseases, injuries and interventions. The management of NP can be challenging due to the complex and frequently inadequate treatment options. Health care professionals must be able to properly diagnose and assess a patient's NP in order to successfully treat their condition.

Choice of Therapy: Multiple guidelines with slightly different approaches exist for the treatment of NP. However, most studies have been based around treatment for painful diabetic neuropathy and below are recommendations for treatment options.

American Diabetes Association (ADA) Algorithm for Management of Diabetic Neuropathy



American Academy of Neurology (AAN) Recommendations for Treatment of Diabetic Neuropathy

Level A (Effective)	Level B (Probably Effective)	
Pregabalin 300 – 600 mg/d	Gabapentin 900 – 3600 mg/day	Dextromethorphan 400 mg/day
	Sodium valproate 500 – 1200 mg/day	Morphine sulfate titrate to 120 mg/day
	Venlafaxine 75 – 225 mg/day	Tramadol 210 mg/day
	Duloxetine 60 – 120 mg/day	Oxycodone max 120 mg/day
	Amitriptyline 25 – 100 mg/day	Capsaicin 0.075% QID
International Association for the S	tudy of Pain (IASP) Stenwise Annroach of Neu	ronathic Pain Treatment

International Association for the Study of Pain (IASP) Stepwise Approach of Neuropathic Pain Treatment



First-Line Pharmacologic Options

	Dosing	Duration	Side Effects	AWP Cost		
Secondary Amine TCAs						
Nortriptyline (PAMELOR)	25 mg at bedtime. Increase by 25 mg daily	6-8 weeks (at least 2 weeks of max tolerated dose)	 Dry mouth, somnolence (initiate therapy at bedtime) 	\$17		
Desipramine (NORPRAMIN)	q 3-7 days. (MAX: 150 mg/day)			\$82		
SNRIs	·	•	•			
Duloxetine (CYMBALTA)	30 mg once daily. After 1 week, increase to 60 mg once daily. (MAX: 60 mg BID)	4 weeks	 Nausea (decreased when Duloxetine is 	\$320		
Venlafaxine (EFFEXOR)	37.5 mg once or twice daily. Increase by 75 mg weekly. (MAX: 225 mg/day)	4-6 weeks	titrated)	\$110		
Calcium Channel	α2-δ ligand	•	•			
Gabapentin (NEURONTIN)	100-300 mg at bedtime or 100-300 mg TID. Increase by 100-300 mg TID q 1-7 days. (MAX: 3600 mg/day); no benefit > 1800 mg/d	3-8 weeks titration (2 weeks at max dose)	 Sedation, dizziness (reduced when dose is titrated) 	\$15		
Pregabalin (LYRICA)	50 mg TID or 75 mg BID. Increase to 300 mg/day after 3-7 days. Then by 150 mg/day q 3-7 days. (MAX: 600 mg/day)	4 weeks	 peripheral edema (dose- dependent ≥ 1800 mg) 	\$550 (B)		

*Pricing is based on AWP Unit Price of all generic/brand (B) formulations available for a 30 day supply of maximum daily dose.

References

- Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. Neurology 2011;76:1758-1765.
- 2 Dworkin R, O'Connor A, Backonja M, et al. Pharmacologic management of neuropathic pain: 3 Evidence-based recommendations Pain 2007:132:237-251
- Boulton A, Vinik A, Arezzo J, et al. Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005;28(4):956-962. 4.
- 5. Red Book Online. Micromedex. www.micromedexsolutions.com (accessed 2016 Feb 2).